In:
Magnetic Resonance in Medicine, Wiley, Vol. 76, No. 3 ( 2016-09), p. 946-952
Abstract:
To facilitate decision making in the oncology clinic, technologies have recently been developed to independently inject and assess multiple anticancer agents directly in a patient's tumor. To increase the flexibility of this approach beyond histological readouts of response, contrast‐enhanced MRI was evaluated for the detection of cell death in living tumors after injection. Methods A six‐needle arrayed microinjection device designed to provide head‐to‐head comparisons of chemotherapy responses in living tumors was used. Xenografted non‐Hodgkin lymphoma tumors in athymic Nude‐Foxn1 nu mice were injected either with different doses of vincristine or with one needle each of vincristine, doxorubicin, bendamustine, prednisolone, mafosfamide, and a vehicle control. To assess drug responses, measurements of enhancement by T1‐weighted contrast‐enhanced MRI were made for individual sites at 24, 48, and 72 h after injection. For comparison, histological evaluations of cell death were obtained after tumor resection. Results Measurements of MRI enhancement at injection sites showed a significant ( P 〈 0.001) positive regression slope as a function of vincristine dose. Average MRI measurements were closely correlated with cell death by hematoxylin and eosin staining (R = 0.81; P = 0.001). Conclusion Contrast‐enhanced MRI has the potential to replace or augment histological analyses of tumor responses to microinjected doses of chemotherapy agents with potential application in selecting optimal chemotherapy regimens. Magn Reson Med 76:946–952, 2016. © 2015 Wiley Periodicals, Inc.
Type of Medium:
Online Resource
ISSN:
0740-3194
,
1522-2594
Language:
English
Publisher:
Wiley
Publication Date:
2016
detail.hit.zdb_id:
1493786-4
